

# ALZHEIMER'S AND PARKINSON'S DISEASES

Strategies for Research and Development

Edited by  
**Abraham Fisher**

*Israel Institute for Biological Research  
Ness-Ziona, Israel*


**Israel Hanin**

*Loyola University Stritch School of Medicine  
Chicago, Illinois*

and

**Chaim Lachman**

*Israel Institute for Biological Research  
Ness-Ziona, Israel*



PLENUM PRESS • NEW YORK AND LONDON

The material on this page was copied from the collection of the National Library of Medicine by a third party and may be protected by U.S. Copyright law.

Library of Congress Cataloging in Publication Data

OHOLO Conference on Basic and Therapeutic Strategies in Alzheimer's and Other Related Neuropsychiatric Disorders (1985: Eilat, Israel)  
Alzheimer's and Parkinson's diseases.  
(Advances in behavioral biology; v. 29)

"Proceedings of the thirtieth OHOLO Conference on Basic and Therapeutic Strategies in Alzheimer's and Other Related Neuropsychiatric Disorders, held in March 24-27, 1985, in Eilat, Israel"—T.p. verso.

Includes bibliographies and index.

1. Parkinsonism—Congresses. 2. Alzheimer's disease—Congresses. I. Fisher, Abraham. II. Hanin, Israel. III. Lachman, Chaim. IV. Title. V. Series. [DNLM: 1. Alzheimer's Disease—congresses. 2. Parkinson Disease—congresses. WM 220 038 1985a]

RC382.047 1985

616.8'3

85-32056

ISBN 0-306-42232-8

OHO

W3  
AD 215  
v. 29  
1986

Proceedings of the thirtieth OHOLO Conference on Basic and Therapeutic Strategies in Alzheimer's and Other Related Neuropsychiatric Disorders, held March 24-27, 1985, in Eilat, Israel

© 1986 Plenum Press, New York  
A Division of Plenum Publishing Corporation  
233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

The material on this page was copied from the collection of the National Library of Medicine by a third party and may be protected by U.S. Copyright law.

PHARMACOLOGICAL ACTIVITY OF NOVEL ANTICHOLINESTERASE AGENTS OF POTENTIAL  
USE IN THE TREATMENT OF ALZHEIMER'S DISEASE

Marta Weinstock<sup>1</sup>, Michal Razin<sup>1</sup>, Michael Chorev<sup>2</sup> & Zeev  
Tashma<sup>2</sup>

Departments of Pharmacology<sup>1</sup> and Medicinal Chemistry<sup>2</sup>  
School of Pharmacy, Hebrew University, Ein Kerem, Jerusalem  
Israel

INTRODUCTION

In dementia of the Alzheimer type there is a selective loss in the cerebral cortex of choline acetyltransferase (CAT), the enzyme that synthesizes acetylcholine (ACh)<sup>1,2</sup>. The degree of dementia and memory impairment that occurs in this condition is well correlated with the decrement in cortical cholinergic transmission<sup>3</sup>. Moreover, scopolamine, a cholinergic antagonist, can cause memory impairment in normal individuals similar to that in aging<sup>4</sup>. These findings suggest that impaired cortical cholinergic transmission may be at least in part responsible for the symptomatology of Alzheimer disease. In support of this suggestion it was found that physostigmine, which prevents the destruction of ACh, can cause memory improvement in Alzheimer patients<sup>5</sup>. The extent of improvement of the symptomatology was closely related to the degree of inhibition of acetylcholinesterase (AChE) in the spinal fluid, and thus to the amount of physostigmine reaching the central nervous system<sup>6</sup>.

As potential therapy for dementia, physostigmine has a number of disadvantages, the most serious of which is its low therapeutic ratio. In most studies in which any improvement in symptomatology was reported, the dose range in which this occurred was very narrow (1-2.5mg orally<sup>6</sup> or 0.25-0.5mg, i.v.<sup>7</sup>), with higher doses causing a decrement in performance or distressing side effects due to peripheral cholinergic overactivity. Another disadvantage is its low chemical stability<sup>8</sup> and short duration of action, which necessitate frequent dosing. Its oral bioavailability is also unpredictable, and it only appears to produce improvement in Alzheimer symptomatology by this route if it is given with lecithin<sup>9</sup>.

The purpose of the present study was to synthesize anticholinesterase agents which readily reach the CNS after parenteral and oral administration; which have a higher therapeutic ratio than that of physostigmine, greater chemical stability, and a longer duration of action. These advantages should make them more suitable than physostigmine for the long term treatment of conditions associated with a deficit in cholinergic transmission in the central nervous system.


Apart from physostigmine, all of the carbamate anticholinesterases which are used medicinally, have a quaternary N-function and thus do not

penetrate the CNS to any significant extent<sup>10</sup>. Almost all the synthetic carbamates with a tertiary N were designed as insecticides, and have a monomethyl substituent on the N of the carbamate. They are thus relatively unstable at physiological pH and of short duration<sup>10</sup>. One such carbamate, miotine, has only been used clinically as a miotic<sup>11</sup>. The dimethyl analogue, has only been used as an insecticide<sup>12</sup>. The effect of other mono or dialkyl substitution on the N of the carbamate of this structure on AChE activity in vitro or in vivo does not appear to have been studied. Accordingly we prepared and tested a series of mono and alkyl derivatives of miotine, the activities of some of which are described. (A patent has been applied for the novel structures). Particular emphasis is placed on their abilities to inhibit brain AChE and on their relative toxicities.

## METHODS

### Preparation of mono- and di-substituted phenyl carbamates

The N-monoalkyl and N,N-dialkyl substituted phenyl carbamates were synthesized from  $\alpha$ -m-hydroxyphenylethyl-dimethylamine (I), which was itself prepared according to the procedure described by Stedman and Stedman<sup>11</sup> with minor modifications, as shown in the scheme below:



For the synthesis of the monoalkylphenyl carbamates, a 2-3 fold molar excess of the alkyl isocyanate was reacted with phenol I in dry benzene at room temperature overnight (see Scheme 1 method A). For the synthesis of the N,N-dialkyl-substituted phenyl carbamates, 1.5-2 fold molar excess of the corresponding carbamoyl chloride was allowed to react with phenol I in dry acetonitrile in the presence of a similar excess of sodium hydride (see Scheme 1 method B). The weak acidity of phenol I required the use of a strong base such as sodium hydride to produce the phenolate which acts as the nucleophile.

All carbamates were obtained as hydrochloride salts by saturating their ethereal solutions with  $\text{HCl(g)}$ . These salts were purified by recrystallization from ethanol-ether. Purity was assessed by t.l.c. on precoated silica gel plates, reversed-phase HPLC, elemental microchemical analysis and  $^1\text{H-n.m.r.}$

### Measurement of antiAChE activity in vitro

Male mice (Sabra strain) weighing 30-40g were sacrificed by cervical dislocation and the whole brain minus cerebellum rapidly removed and weighed. The brains from 10 mice were homogenized in 1ml/100g wet weight phosphate buffer 0.1M pH 8.0, centrifuged at 12,000 rpm and the supernatant, discarded. The pellet was mixed with a similar volume as above of buffer 0.1M pH 8.0 containing 1% Triton using a Vortex Genie at maximum speed for 1 min. The mixture was centrifuged and the supernatant which contained most of the solubilized AChE, was used for subsequent determinations of anticholinesterase activity.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.